Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03560609 · ClinicalTrials.gov registry record · NA
Optic Nerve Head Structural Response to IOP Elevation in Patients With Keratoconus
A NA study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT03560609: Clinical Trial NA study, sponsored by NYU Langone Health.
NCT03560609 is a NA study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03560609, a NA study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
The mechanism by which vision loss in glaucoma occurs is still unknown, but it is clear that increased Intraocular Pressure (IOP) is a major risk factor. It is also thought that the lamina cribrosa (LC) is a site of primary damage during the pathogenesis of the disease. The changes caused by intraocular pressure (IOP) modulation at the level of the optic nerve head and LC will be evaluated in the present study. Subjects with keratoconus exhibit abnormal collagen properties that can impair their LC behavior. By evaluating their lamina biomechanical response we can advance our understanding on the role of the lamina in glaucoma pathogenesis. A better understanding of the process will ultimately lead to improved detection and management of glaucoma. It is hypothesized that subjects with keratoconus have an abnormal biomechanical response of the lamina cribrosa in response to IOP modulation.
Primary Outcome
Determination of tissue deformation will be obtained from OCT images.
Interventions
- DEVICE Optical Coherence Tomography (OCT)
- DEVICE Ophthalmodynamometer
- DEVICE Goldmann applanation tonometer
- DEVICE Pentacam
- DEVICE ORA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-11-15 |
| Est. Completion | 2024-01-19 |
| Phase | NA |
Why NCT03560609 stopped before completion
NCT03560609 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 5 interventions - of which Optical Coherence Tomography (OCT) is the first listed.
NCT03560609 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03560609 about?
NCT03560609 is a clinical study titled "Optic Nerve Head Structural Response to IOP Elevation in Patients With Keratoconus". The mechanism by which vision loss in glaucoma occurs is still unknown, but it is clear that increased Intraocular Pressure (IOP) is a major risk factor. It is also thought that the lamina cribrosa (LC) is a site of primary damage during the pathogenesis of the disease. The changes caused by intraoc...
What is the current status of trial NCT03560609?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2018-11-15. Estimated completion is 2024-01-19.
What interventions are being tested in trial NCT03560609?
The interventions under investigation include: Optical Coherence Tomography (OCT) (DEVICE), Ophthalmodynamometer (DEVICE), Goldmann applanation tonometer (DEVICE), Pentacam (DEVICE), ORA (DEVICE).
Who is sponsoring clinical trial NCT03560609?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03560609's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI